FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138608959> ?p ?o ?g. }

• W2138608959 endingPage "571" @default.
• W2138608959 startingPage "562" @default.
• W2138608959 abstract "In situ cytotoxic gene therapy can potentially trigger a systemic immune response, which could impact occult metastatic disease. We are currently conducting three clinical trials using in situ adenoviral vector mediated herpes simplex virus-thymidine kinase (HSV-tk) gene delivery followed by the HSV-tk prodrug ganciclovir (GCV) or valacyclovir (VCV). This study evaluates the systemic T-cell response after gene therapy in each trial.The study protocol included three separate clinical trials in the Baylor Prostate Cancer SPORE Program: Trial A gene therapy in prostate cancer patients failing radiotherapy (36 patients), Trial B neoadjuvant gene therapy in pre-radical prostatectomy patients (22 patients), and Trial C gene therapy in combination with radiotherapy for prostate cancer (27 patients). Heparinized blood was collected at the time of vector injection and at selected intervals afterward. A complete blood count was performed, and peripheral blood lymphocytes were analyzed by fluorescent antibody cell sorting after labeling with dual color-labeled antibody pairs.The pretreatment mean percentage of activated CD8+ T cells (DR+CD8+ T cells) was 12.23%, 16.72%, and 14.09% (Trials A, B, and C, respectively). Two weeks posttreatment, this increased to 22.87%, 26.15%, and 39.04% (Trials A, B, and C, respectively), and these increases were statistically significant (p = 0.0188, p = 0.0010, p < 0.0001, respectively). The increase of DR+CD8+ T cells was significantly larger in Trial C than in Trial A (p = 0.0044) or Trial B (p = 0.0288). Total CD8+ T cells significantly increased at 2 weeks posttreatment in Trial B and C (p = 0.0013, p = 0.0004, respectively). Interestingly, only in Trial C were significant increases in activated CD4+ T cells seen at 2 weeks (p = 0.0035).This is the first report of systemic T-cell responses after HSV-tk+GCV/VCV gene therapy under three clinical trial conditions. There was an increase in activated CD8+ T cells in the peripheral blood after vector injection, suggesting the potential for activation of components of cell-mediated immune response in all trial conditions. The addition of radiotherapy to in situ gene therapy seems to further increase the total CD8+ T cells and activated CD4+ T cells." @default.
• W2138608959 created "2016-06-24" @default.
• W2138608959 creator A5007266497 @default.
• W2138608959 creator A5010061869 @default.
• W2138608959 creator A5014373184 @default.
• W2138608959 creator A5017101446 @default.
• W2138608959 creator A5024670184 @default.
• W2138608959 creator A5025245246 @default.
• W2138608959 creator A5037000397 @default.
• W2138608959 creator A5037470251 @default.
• W2138608959 creator A5041990261 @default.
• W2138608959 creator A5042000405 @default.
• W2138608959 creator A5065048363 @default.
• W2138608959 creator A5065202811 @default.
• W2138608959 creator A5072634480 @default.
• W2138608959 creator A5073982399 @default.
• W2138608959 creator A5086586078 @default.
• W2138608959 creator A5087750113 @default.
• W2138608959 date "2004-06-01" @default.
• W2138608959 modified "2023-09-27" @default.
• W2138608959 title "Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients" @default.
• W2138608959 cites W1444462873 @default.
• W2138608959 cites W1964969453 @default.
• W2138608959 cites W1972601062 @default.
• W2138608959 cites W1977039120 @default.
• W2138608959 cites W1980424217 @default.
• W2138608959 cites W1983806918 @default.
• W2138608959 cites W1990439902 @default.
• W2138608959 cites W2012315955 @default.
• W2138608959 cites W2013474978 @default.
• W2138608959 cites W2014180431 @default.
• W2138608959 cites W2015597117 @default.
• W2138608959 cites W2020356718 @default.
• W2138608959 cites W2024356087 @default.
• W2138608959 cites W2031477951 @default.
• W2138608959 cites W2038590203 @default.
• W2138608959 cites W2048604915 @default.
• W2138608959 cites W2054125735 @default.
• W2138608959 cites W2075718053 @default.
• W2138608959 cites W2076959899 @default.
• W2138608959 cites W2083314535 @default.
• W2138608959 cites W2083500661 @default.
• W2138608959 cites W2085834739 @default.
• W2138608959 cites W2089751686 @default.
• W2138608959 cites W2109694492 @default.
• W2138608959 cites W2114214906 @default.
• W2138608959 cites W2115182182 @default.
• W2138608959 cites W2130559643 @default.
• W2138608959 cites W2131098994 @default.
• W2138608959 cites W2138733343 @default.
• W2138608959 cites W2145829662 @default.
• W2138608959 cites W2152561234 @default.
• W2138608959 cites W2155775783 @default.
• W2138608959 cites W2167919463 @default.
• W2138608959 cites W2334127382 @default.
• W2138608959 doi "https://doi.org/10.1016/j.ijrobp.2004.01.020" @default.
• W2138608959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15145177" @default.
• W2138608959 hasPublicationYear "2004" @default.
• W2138608959 type Work @default.
• W2138608959 sameAs 2138608959 @default.
• W2138608959 citedByCount "34" @default.
• W2138608959 countsByYear W21386089592012 @default.
• W2138608959 countsByYear W21386089592014 @default.
• W2138608959 countsByYear W21386089592015 @default.
• W2138608959 countsByYear W21386089592016 @default.
• W2138608959 countsByYear W21386089592017 @default.
• W2138608959 countsByYear W21386089592021 @default.
• W2138608959 crossrefType "journal-article" @default.
• W2138608959 hasAuthorship W2138608959A5007266497 @default.
• W2138608959 hasAuthorship W2138608959A5010061869 @default.
• W2138608959 hasAuthorship W2138608959A5014373184 @default.
• W2138608959 hasAuthorship W2138608959A5017101446 @default.
• W2138608959 hasAuthorship W2138608959A5024670184 @default.
• W2138608959 hasAuthorship W2138608959A5025245246 @default.
• W2138608959 hasAuthorship W2138608959A5037000397 @default.
• W2138608959 hasAuthorship W2138608959A5037470251 @default.
• W2138608959 hasAuthorship W2138608959A5041990261 @default.
• W2138608959 hasAuthorship W2138608959A5042000405 @default.
• W2138608959 hasAuthorship W2138608959A5065048363 @default.
• W2138608959 hasAuthorship W2138608959A5065202811 @default.
• W2138608959 hasAuthorship W2138608959A5072634480 @default.
• W2138608959 hasAuthorship W2138608959A5073982399 @default.
• W2138608959 hasAuthorship W2138608959A5086586078 @default.
• W2138608959 hasAuthorship W2138608959A5087750113 @default.
• W2138608959 hasBestOaLocation W21386089591 @default.
• W2138608959 hasConcept C104317684 @default.
• W2138608959 hasConcept C111599444 @default.
• W2138608959 hasConcept C121608353 @default.
• W2138608959 hasConcept C126322002 @default.
• W2138608959 hasConcept C143998085 @default.
• W2138608959 hasConcept C167672396 @default.
• W2138608959 hasConcept C185592680 @default.
• W2138608959 hasConcept C203014093 @default.
• W2138608959 hasConcept C2780192828 @default.
• W2138608959 hasConcept C509974204 @default.
• W2138608959 hasConcept C535046627 @default.
• W2138608959 hasConcept C55493867 @default.
• W2138608959 hasConcept C71924100 @default.

• next